ResearchRSSYesterday
Scientists discovered that people with ALS who carry a specific gene variant called APOE4 (known to increase Alzheimer's risk) are more likely to have toxic protein clumps spread to more areas of their brain. This suggests the same gene may affect how disease progresses differently in ALS patients. The finding could help doctors better understand why ALS affects people differently.
WHY IT MATTERSIf you have ALS and carry the APOE4 variant, this research suggests you may experience different patterns of disease progression, which could eventually help doctors predict outcomes and tailor treatment approaches for individual patients.
ResearchRSS3 days ago
A new study found that statin drugs, which lower cholesterol, do not slow down ALS or change how long people with ALS live. This means doctors should prescribe statins to ALS patients based on their cholesterol levels, not because of their ALS diagnosis.
WHY IT MATTERSIf you have ALS and high cholesterol, you can now feel confident that taking statins for your heart health won't interfere with your ALS treatment or make your disease worse.
ResearchRSS4 days ago
Scientists found that some people with ALS get worse faster than others because of differences in how their immune cells cause inflammation. The study shows that the amount of inflammation in the spinal cord isn't the main factor — instead, it's the type of immune activity that matters. This discovery could lead to new treatments that slow down ALS by targeting specific inflammatory markers.
WHY IT MATTERSIf doctors can identify which inflammatory markers predict faster progression, they may be able to personalize treatment plans and potentially slow disease advancement for individual ALS patients.
ResearchRSSMay 15
Scientists have created a new medicine made from RNA (a molecule similar to DNA) that may help reduce clumping of a protein called TDP-43 in people with ALS. ALS is a disease that affects nerve cells and causes muscle weakness. This new therapy works by stopping the protein from clumping together, which is a major problem in ALS. The research team studied exactly how this medicine works at the molecular level.
WHY IT MATTERSThis research targets TDP-43 clumping, which is a core driver of ALS neurodegeneration, potentially offering a disease-modifying approach for patients who currently have limited treatment options.
ResearchRSSMay 11
Scientists found that a system in nerve cells that normally cleans up damaged proteins isn't working properly in people with ALS (a disease that affects movement). This broken cleanup system might be a target for new treatments that could slow down ALS. The discovery could lead to therapies that help these nerve cells work better.
WHY IT MATTERSIf researchers can develop drugs that fix this protein recycling system, it could offer a new way to slow ALS progression by addressing a root cause of nerve cell damage rather than just treating symptoms.
ResearchRSSMay 8
A new free tool called SAVA AI has been launched to help people with ALS (a disease that affects nerve cells controlling muscles) quickly find clinical trials they might be able to join. The tool uses artificial intelligence to match patients with research studies in seconds through a website or mobile app. This makes it easier for ALS patients to discover opportunities to participate in medical research.
WHY IT MATTERSALS patients now have a fast, free way to discover clinical trials they're eligible for without spending hours searching multiple websites or calling research centers.
ResearchRSSMay 8
Scientists are developing new treatments for ALS, a serious disease that affects nerve cells and muscles. These treatments work in different ways—some target genes, others help the immune system, and some use new methods to deliver medicine to the brain. While ALS is still very serious, people are living longer with better care, and doctors hope these new treatments will help slow down the disease.
WHY IT MATTERSIf you or a loved one has ALS, this news means multiple new treatment approaches are in development that could slow disease progression or eventually modify the underlying disease process, offering hope beyond current symptom management.
ResearchRSSApr 27
A new study from Finland found that deaths from ALS (a disease that affects nerve cells controlling muscles) have nearly doubled over the last 30 years. The increase is especially noticeable in older adults. Researchers aren't sure why this is happening, and similar increases haven't been reported in other countries.
WHY IT MATTERSIf ALS death rates are rising in Finland, understanding why could help identify preventable risk factors or early warning signs that might apply to ALS patients elsewhere.